In last trading session, ZyVersa Therapeutics Inc (NASDAQ:ZVSA) saw 74935.0 shares changing hands with its beta currently measuring 0.35. Company’s recent per share price level of $1.18 trading at -$0.05 or -3.87% at ring of the bell on the day assigns it a market valuation of $2.96M. That closing price of ZVSA’s stock is at a discount of -2018.64% from its 52-week high price of $25.00 and is indicating a premium of 16.95% from its 52-week low price of $0.98. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 90440.0 shares which gives us an average trading volume of 1.29 million if we extend that period to 3-months.
ZyVersa Therapeutics Inc (NASDAQ:ZVSA) trade information
Upright in the red during last session for losing -3.87%, in the last five days ZVSA remained trading in the green while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $1.18 price level, adding 7.81% to its value on the day. ZyVersa Therapeutics Inc’s shares saw a change of 11.32% in year-to-date performance and have moved 11.32% in past 5-day. ZyVersa Therapeutics Inc (NASDAQ:ZVSA) showed a performance of 15.69% in past 30-days. Number of shares sold short was 45485.0 shares which calculate 0.19 days to cover the short interests.
ZyVersa Therapeutics Inc (ZVSA) estimates and forecasts
Statistics highlight that ZyVersa Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -80.91% of value to its shares in past 6 months, showing an annual growth rate of 97.65% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
ZyVersa Therapeutics Inc (NASDAQ:ZVSA)’s Major holders
Insiders are in possession of 0.61% of company’s total shares while institution are holding 4.47 percent of that, with stock having share float percentage of 4.50%. Investors also watch the number of corporate investors in a company very closely, which is 4.47% institutions for ZyVersa Therapeutics Inc that are currently holding shares of the company.
